Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Langdon L. Miller(Gilead Sciences (United States)), Charles D. Blanke(SWOG Cancer Research Network), Lee S. Rosen(APLA Health), Stephen P. Ackland(Mater Misericordiae Hospital), Nicoletta Pirotta(American Pharmacists Association), Paula K. Locker(American Pharmacists Association), Louis Fehrenbacher(Kaiser Permanente Vallejo Medical Center), Jean A. Maroun(American Society of Clinical Oncology), Malcolm J. Moore(University Health Network), Gary Elfring(American Pharmacists Association), John V. Cox(Southwestern Medical Center)
Cited by 3,009
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k